Form 4: Regeneron Executive Daniel P. Van Plew Reports Stock Transactions

Regeneron Pharmaceuticals executive Daniel P. Van Plew reports acquisition of restricted stock and stock options, along with disposition of shares to cover tax obligations.

Summary

• Daniel P. Van Plew, an Executive Vice President at Regeneron Pharmaceuticals, reported several transactions involving the company's stock.
• On December 6, 2024, Van Plew acquired 3,499 shares of common stock as a restricted stock award, with vesting scheduled for December 6, 2026 and December 6, 2028.
• Also on December 6, 2024, he was granted a non-qualified stock option for 13,472 shares at an exercise price of $771.64, vesting in four equal annual installments starting one year after the grant date.
• On December 9, 2024, 492 shares were disposed of to cover tax obligations at a price of $787 per share.
• Following these transactions, Van Plew directly owns 35,761 shares of common stock and indirectly owns 1,100 shares through a 401(k) plan.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and does not indicate any significant positive or negative sentiment. The stock transactions are routine and expected.

Positives

• The grant of restricted stock and stock options to a key executive like Daniel P. Van Plew suggests the company's commitment to incentivizing its leadership.
• The vesting schedule of the restricted stock and stock options encourages long-term performance and retention of the executive.

Negatives

• The disposal of 492 shares to cover tax obligations, while a common practice, slightly reduces Van Plew's direct holdings in the company.

Risks

• The value of the stock options is dependent on the future performance of Regeneron's stock price.
• The vesting schedule of the restricted stock and stock options could be impacted by changes in employment status.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies. It reflects the typical compensation practices for executives, including stock options and restricted stock awards.

Comparison to Industry Standards

• Stock option grants and restricted stock awards are common forms of executive compensation in the pharmaceutical industry.
• The vesting schedules for the restricted stock and stock options are typical for long-term incentive plans.
• The disposal of shares to cover tax obligations is a standard practice among executives who receive equity compensation.

Stakeholder Impact

• The stock transactions may have a minor impact on the overall shareholding structure of the company.
• The executive compensation package is designed to align the interests of management with those of shareholders.

Key Dates

Keywords

Regeneron, Stock Options, Restricted Stock, Insider Trading, Executive Compensation, Form 4, Daniel P. Van Plew